Literature DB >> 12452860

Preferential expression of alphaEbeta7 integrin (CD103) on CD8+ T cells in the psoriatic epidermis: regulation by interleukins 4 and 12 and transforming growth factor-beta.

Y Teraki1, T Shiohara.   

Abstract

BACKGROUND: Intraepidermal T lymphocytes are a critical element for sustaining the lesional pathology of psoriasis. Integrin alphaEbeta7 (CD103), a ligand for E-cadherin, may play a role in the localization of pathogenic T cells within the epidermis of psoriatic lesions. However, little information is available regarding alphaEbeta7 expression on intraepidermal T cells in psoriasis.
OBJECTIVES: To examine alphaEbeta7 expression on intraepidermal T cells in psoriatic lesions and the regulation of alphaEbeta7 expression on T cells in response to cytokines.
METHODS: T-cell expression of alphaEbeta7 was examined by immunohistochemistry and flow cytometry. In vitro regulation of alphaEbeta7 expression on CD4+ or CD8+ T cells purified from peripheral blood of healthy donors was also examined.
RESULTS: Immunohistochemical staining revealed expression of alphaEbeta7 on a greater proportion of epidermal T cells than dermal T cells. Nearly 30% of intraepidermal CD4+ T cells were found to express alphaEbeta7 on flow cytometry, whereas more than 80% of intraepidermal CD8+ T cells expressed this integrin. In contrast, few T cells expressed alphaEbeta7 in the peripheral blood of psoriatic patients. The in vitro culture experiment confirmed that alphaEbeta7 was preferentially expressed on CD8+ T cells after stimulation with anti-CD3 monoclonal antibodies. Addition of transforming growth factor-beta and interleukin-4 upregulated alphaEbeta7 expression on T cells, whereas interleukin 12 downregulated this. Furthermore, alphaEbeta7 expression on established memory CD8+ T cells was not so reversible as that on CD4+ T cells.
CONCLUSIONS: Preferential and stable expression of alphaEbeta7 on CD8+ T cells may be involved in the lesional pathology of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452860     DOI: 10.1046/j.1365-2133.2002.05005.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.

Authors:  E G Stefanich; D M Danilenko; H Wang; S O'Byrne; R Erickson; T Gelzleichter; H Hiraragi; H Chiu; S Ivelja; S Jeet; S Gadkari; O Hwang; F Fuh; C Looney; K Howell; V Albert; M Balazs; C Refino; S Fong; S Iyer; M Williams
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 2.  Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders.

Authors:  Ling Chen; Zhu Shen
Journal:  Cell Mol Immunol       Date:  2019-10-08       Impact factor: 11.530

3.  Local immunity by tissue-resident CD8(+) memory T cells.

Authors:  Thomas Gebhardt; Laura K Mackay
Journal:  Front Immunol       Date:  2012-11-09       Impact factor: 7.561

4.  Systemic sensitization with the protein allergen ovalbumin augments local sensitization in atopic dermatitis.

Authors:  Jane Yoo; Anne M Manicone; John K McGuire; Ying Wang; William C Parks
Journal:  J Inflamm Res       Date:  2014-02-20

Review 5.  Resident-Memory T Cells in Tissue-Restricted Immune Responses: For Better or Worse?

Authors:  Karin Steinbach; Ilena Vincenti; Doron Merkler
Journal:  Front Immunol       Date:  2018-11-30       Impact factor: 7.561

6.  SMAD4 and TGFβ are architects of inverse genetic programs during fate determination of antiviral CTLs.

Authors:  Karthik Chandiran; Jenny E Suarez-Ramirez; Yinghong Hu; Evan R Jellison; Zeynep Ugur; Jun Siong Low; Bryan McDonald; Susan M Kaech; Linda S Cauley
Journal:  Elife       Date:  2022-08-09       Impact factor: 8.713

Review 7.  Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.

Authors:  M T Tang; M E Keir; R Erickson; E G Stefanich; F K Fuh; T Ramirez-Montagut; J M McBride; D M Danilenko
Journal:  Aliment Pharmacol Ther       Date:  2018-03-30       Impact factor: 8.171

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.